2023
DOI: 10.1002/ajh.26945
|View full text |Cite
|
Sign up to set email alerts
|

Rivaroxaban versus nadroparin for thromboprophylaxis following thoracic surgery for lung cancer: A randomized, noninferiority trial

Abstract: The benefit of rivaroxaban in thromboprophylaxis after oncologic lung surgery remains unknown. To evaluate the efficacy and safety of rivaroxaban, patients who underwent thoracic surgery for lung cancer were enrolled, and randomly assigned to rivaroxaban or nadroparin groups in a 1:1 ratio; anticoagulants were initiated 12–24 h after surgery and continued until discharge. Four hundred participants were required according to a noninferiority margin of 2%, assuming venous thromboembolism (VTE) occurrence rates o… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
7
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(7 citation statements)
references
References 65 publications
0
7
0
Order By: Relevance
“…A total of 10 studies (three RCTs [ 21 , 22 , 32 ] and 7observational studies [ 33 39 ]), encompassing 3054patients, were included in the systematic review. Of the 10 studies, eight (three RCTs [ 21 , 22 , 32 ] and five observational studies [ 34 , 36 39 ]) were included in the pooled analysis comparing the efficacy and safety of thromboprophylaxis after cancer surgery within 30 days. The types of cancer included gynecological malignancies ( n = 5), urological malignancies ( n = 3), Pancreatic adenocarcinoma ( n = 1) and lung cancer ( n = 1).…”
Section: Resultsmentioning
confidence: 99%
See 3 more Smart Citations
“…A total of 10 studies (three RCTs [ 21 , 22 , 32 ] and 7observational studies [ 33 39 ]), encompassing 3054patients, were included in the systematic review. Of the 10 studies, eight (three RCTs [ 21 , 22 , 32 ] and five observational studies [ 34 , 36 39 ]) were included in the pooled analysis comparing the efficacy and safety of thromboprophylaxis after cancer surgery within 30 days. The types of cancer included gynecological malignancies ( n = 5), urological malignancies ( n = 3), Pancreatic adenocarcinoma ( n = 1) and lung cancer ( n = 1).…”
Section: Resultsmentioning
confidence: 99%
“…Two of the three randomized controlled trials were adjudicated to a low risk of bias [ 21 , 32 ] and one had some concern because the trial was stopped due to a lower-than-expected event rate [ 22 ] (Fig. 2 A).…”
Section: Resultsmentioning
confidence: 99%
See 2 more Smart Citations
“…However, prophylactic anticoagulation also has drawbacks, including increased risk of bleeding, costs, patient discomfort and inconvenience. Oral alternatives such as direct-acting oral anticoagulants (DOACs) obviate the need for daily injections with documented comparable efficacy to LMWH [ 19 , 20 ]. This calls for a need to personalize decision-making about thromboprophylaxis and consider extended prophylaxis for high-risk patients such as those with large resections, advanced cancer stage, central tumours compressing veins or undergoing treatment with systemic therapies (e.g.…”
Section: Discussionmentioning
confidence: 99%